JP5647998B2 - 免疫抑制剤としてのチアゾロピリミジン調節因子 - Google Patents

免疫抑制剤としてのチアゾロピリミジン調節因子 Download PDF

Info

Publication number
JP5647998B2
JP5647998B2 JP2011553476A JP2011553476A JP5647998B2 JP 5647998 B2 JP5647998 B2 JP 5647998B2 JP 2011553476 A JP2011553476 A JP 2011553476A JP 2011553476 A JP2011553476 A JP 2011553476A JP 5647998 B2 JP5647998 B2 JP 5647998B2
Authority
JP
Japan
Prior art keywords
amino
thiazolo
piperazin
pyrimidin
fluorophenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2011553476A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012520269A5 (enExample
JP2012520269A (ja
Inventor
ヘルデヴィユン、ピエト
ヨンゲ、スティーブン デ
ヨンゲ、スティーブン デ
− ジー ガオ、リン
− ジー ガオ、リン
− イエオン ヤン、ミ
− イエオン ヤン、ミ
− デロイドンク、バルト ファン
− デロイドンク、バルト ファン
ヨーゼフ アルベルト ヴァエル、マルク
ヨーゼフ アルベルト ヴァエル、マルク
リン、ユアン
フェルディナンド ヘルマン、ジャン
フェルディナンド ヘルマン、ジャン
ティエリー アンドレ ミシェル ルア、
ティエリー アンドレ ミシェル ルア、
Original Assignee
カトリーケ ユニバーシテイト ルーヴェン、ケー.ユー. ルーヴェン アール アンド ディー
カトリーケ ユニバーシテイト ルーヴェン、ケー.ユー. ルーヴェン アール アンド ディー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0904373A external-priority patent/GB0904373D0/en
Priority claimed from GB0904353A external-priority patent/GB0904353D0/en
Priority claimed from GB0911022A external-priority patent/GB0911022D0/en
Application filed by カトリーケ ユニバーシテイト ルーヴェン、ケー.ユー. ルーヴェン アール アンド ディー, カトリーケ ユニバーシテイト ルーヴェン、ケー.ユー. ルーヴェン アール アンド ディー filed Critical カトリーケ ユニバーシテイト ルーヴェン、ケー.ユー. ルーヴェン アール アンド ディー
Publication of JP2012520269A publication Critical patent/JP2012520269A/ja
Publication of JP2012520269A5 publication Critical patent/JP2012520269A5/ja
Application granted granted Critical
Publication of JP5647998B2 publication Critical patent/JP5647998B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/26Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32Nitrogen atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/55131,4-Benzodiazepines, e.g. diazepam or clozapine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/02Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/18Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2011553476A 2009-03-13 2010-03-15 免疫抑制剤としてのチアゾロピリミジン調節因子 Expired - Fee Related JP5647998B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GB0904373A GB0904373D0 (en) 2009-03-13 2009-03-13 Novel thienopyrimidines
GB0904353A GB0904353D0 (en) 2009-03-13 2009-03-13 Novel thiazolopyrimidines
GB0904353.0 2009-03-13
GB0904373.8 2009-03-13
GB0911022A GB0911022D0 (en) 2009-06-26 2009-06-26 Novel purines
GB0911022.2 2009-06-26
PCT/EP2010/053318 WO2010103130A2 (en) 2009-03-13 2010-03-15 Novel bicyclic heterocycles

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014228403A Division JP6021880B2 (ja) 2009-03-13 2014-11-10 免疫抑制剤としてのチアゾロピリミジン調節因子

Publications (3)

Publication Number Publication Date
JP2012520269A JP2012520269A (ja) 2012-09-06
JP2012520269A5 JP2012520269A5 (enExample) 2013-05-02
JP5647998B2 true JP5647998B2 (ja) 2015-01-07

Family

ID=42181129

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2011553476A Expired - Fee Related JP5647998B2 (ja) 2009-03-13 2010-03-15 免疫抑制剤としてのチアゾロピリミジン調節因子
JP2014228403A Expired - Fee Related JP6021880B2 (ja) 2009-03-13 2014-11-10 免疫抑制剤としてのチアゾロピリミジン調節因子

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2014228403A Expired - Fee Related JP6021880B2 (ja) 2009-03-13 2014-11-10 免疫抑制剤としてのチアゾロピリミジン調節因子

Country Status (6)

Country Link
US (2) US8901132B2 (enExample)
EP (2) EP2923734B1 (enExample)
JP (2) JP5647998B2 (enExample)
CA (2) CA2754890C (enExample)
ES (2) ES2543216T3 (enExample)
WO (1) WO2010103130A2 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2035369T3 (pl) 2006-07-05 2015-02-27 Fibrotech Therapeutics Pty Ltd Związki terapeutyczne
ES2543216T3 (es) * 2009-03-13 2015-08-17 Katholieke Universiteit Leuven, K.U. Leuven R&D Moduladores de tiazolopirimidina como agentes inmunosupresores
CN102574843B (zh) * 2009-10-22 2015-06-17 法博太科制药有限公司 抗纤维化剂的稠环类似物
GB201012889D0 (en) 2010-08-02 2010-09-15 Univ Leuven Kath Antiviral activity of novel bicyclic heterocycles
GB201015411D0 (en) 2010-09-15 2010-10-27 Univ Leuven Kath Anti-cancer activity of novel bicyclic heterocycles
GB201114212D0 (en) 2011-08-18 2011-10-05 Ucb Pharma Sa Therapeutic agents
GB201115665D0 (en) 2011-09-09 2011-10-26 Univ Leuven Kath Autoimmune and inflammatory disorder therapy
US20130102601A1 (en) 2011-10-21 2013-04-25 F. Hoffmann-La Roche Ltd Pyrimidin-4-one derivatives and their use in the treatment, amelioration or prevention of a viral disease
GB201119401D0 (en) 2011-11-10 2011-12-21 Ucb Pharma Sa Therapeutic agents
GB201217704D0 (en) * 2012-10-03 2012-11-14 Ucb Pharma Sa Therapeutic agents
PE20151767A1 (es) * 2012-12-20 2015-12-11 Ucb Biopharma Sprl Derivados de pirazolo-pirimidina terapeuticamente activos
CN103044460B (zh) * 2013-01-30 2015-02-25 石家庄学院 3,5,7-三苯基-5H-噻唑并[3,2-a]嘧啶类衍生物及应用
BR112015025296A2 (pt) * 2013-04-05 2017-07-18 Polichem Sa uso de pidotimod para o tratamento de doença inflamatória intestinal
RU2016110852A (ru) * 2013-09-27 2017-10-30 Нимбус Айрис, Инк. Ингибиторы irak и их применения
TWI648281B (zh) 2013-10-17 2019-01-21 日商安斯泰來製藥股份有限公司 含硫二環式化合物
CN104892589A (zh) * 2014-03-07 2015-09-09 中国科学院上海药物研究所 一类杂环化合物、其制备方法和用途
GB201410817D0 (en) * 2014-06-17 2014-07-30 Ucb Biopharma Sprl And Katholieke Universiteit Leuven K U Leuven R & D Therapeutic agents
US9822127B2 (en) * 2014-07-23 2017-11-21 The Board Of Trustees Of The Leland Stanford Junior University GAK modulators as antivirals
MX2017005462A (es) 2014-11-05 2017-07-28 Flexus Biosciences Inc Agentes inmunorreguladores.
UY36390A (es) 2014-11-05 2016-06-01 Flexus Biosciences Inc Compuestos moduladores de la enzima indolamina 2,3-dioxigenasa (ido), sus métodos de síntesis y composiciones farmacéuticas que los contienen
GB201517263D0 (en) 2015-09-30 2015-11-11 Ucb Biopharma Sprl And Katholieke Universiteit Leuven Therapeutic agents
GB201521767D0 (en) 2015-12-10 2016-01-27 Ucb Biopharma Sprl And Katholieke Universiteit Leuven K U Leuven R&D Therapeutic agents
MX2019009235A (es) 2017-02-03 2019-12-11 Certa Therapeutics Pty Ltd Compuestos antifibroticos.
US11952387B2 (en) 2018-08-21 2024-04-09 Kyorin Pharmaceutical Co., Ltd Bicyclic heteroaromatic ring derivative

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2512572A (en) 1950-06-20 Substituted pteridines and method
BE791242A (fr) * 1971-11-11 1973-05-10 Thomae Gmbh Dr K Nouvelles thiazolo(5,4-d)pyrimidines
US4127118B1 (en) 1977-03-16 1995-12-19 Alvaro Latorre Method of effecting and enhancing an erection
ZA857647B (en) * 1984-10-12 1986-05-28 Warner Lambert Co Purine derivatives
US5057517A (en) * 1987-07-20 1991-10-15 Merck & Co., Inc. Piperazinyl derivatives of purines and isosteres thereof as hypoglycemic agents
IL87149A (en) * 1987-07-20 1994-05-30 Merck & Co Inc 6-Piperazinyl derivatives of purine and its 3- and 9-deaza isosteres, their preparation and pharmaceutical compositions containing them
GB9221220D0 (en) 1992-10-09 1992-11-25 Sandoz Ag Organic componds
US5780462A (en) 1995-12-27 1998-07-14 American Home Products Corporation Water soluble rapamycin esters
JP2001097979A (ja) * 1999-07-28 2001-04-10 Takeda Chem Ind Ltd 縮合複素環化合物、その製造法および用途
US6331547B1 (en) 1999-08-18 2001-12-18 American Home Products Corporation Water soluble SDZ RAD esters
DE60101372T2 (de) * 2000-02-11 2004-10-14 Astrazeneca Ab Pyrimidinverbindungen und ihre verwendung als modulatoren der chemokin-rezeptor-aktivität
US6440991B1 (en) 2000-10-02 2002-08-27 Wyeth Ethers of 7-desmethlrapamycin
JP2004028376A (ja) 2002-06-21 2004-01-29 Hino Motors Ltd Egrクーラ
JP4768265B2 (ja) * 2002-10-15 2011-09-07 シンタ ファーマシューティカルズ コーポレーション 新規化合物
AU2003302657B8 (en) * 2002-12-04 2009-12-03 Eisai R&D Management Co., Ltd. Fused 1,3-dihydroimidazole ring compounds
ES2217956B1 (es) * 2003-01-23 2006-04-01 Almirall Prodesfarma, S.A. Nuevos derivados de 4-aminotieno(2,3-d)pirimidin-6-carbonitrilo.
ES2324536T7 (es) 2003-06-11 2012-03-16 Xention Limited Derivados de tenopirimidina como inhibidores de los canales de potasio.
DE10348023A1 (de) * 2003-10-15 2005-05-19 Imtm Gmbh Neue Alanyl-Aminopeptidasen-Inhibitoren zur funktionellen Beeinflussung unterschiedlicher Zellen und zur Behandlung immunologischer, entzündlicher, neuronaler und anderer Erkrankungen
US20080269238A1 (en) 2004-04-01 2008-10-30 Takeda Pharmaceutical Company Limited Thiazolopyrimidine Derivative
GB0407723D0 (en) * 2004-04-05 2004-05-12 Novartis Ag Organic compounds
US7576080B2 (en) 2004-12-23 2009-08-18 Memory Pharmaceuticals Corporation Certain thienopyrimidine derivatives as phosphodiesterase 10 inhibitors
FR2880626B1 (fr) * 2005-01-13 2008-04-18 Aventis Pharma Sa Derives de la purine, compositions les contenant et utilisation
EP1844052A1 (en) * 2005-01-26 2007-10-17 Pharmacia & Upjohn Company LLC Thieno[2,3-d]pyrimidine compounds as inhibitors of adp-mediated platelets aggregation
US20090149452A1 (en) 2005-07-01 2009-06-11 Nippon Chemiphar Co., Ltd. Xanthine oxidase inhibitor
GB0526246D0 (en) * 2005-12-22 2006-02-01 Novartis Ag Organic compounds
WO2007084815A2 (en) 2006-01-19 2007-07-26 Janssen Pharmaceutica, N.V. Substituted thienopyrimidine kinase inhibitors
KR100846988B1 (ko) 2006-03-06 2008-07-16 제일약품주식회사 신규한 티에노피리미딘 유도체 또는 이의 약학적으로허용가능한 염, 이의 제조방법 및 이를 함유하는 약학조성물
KR101402474B1 (ko) * 2006-04-26 2014-06-19 제넨테크, 인크. 포스포이노시티드 3-키나제 억제제 화합물 및 이를 포함하는 약학적 조성물
CA2651769C (en) * 2006-05-18 2013-12-17 F. Hoffmann-La Roche Ag Thiazolo-pyramidine / pyridine urea derivatives as adenosine a2b receptor antagonists
WO2008005303A2 (en) 2006-06-30 2008-01-10 Janssen Pharmaceutica N.V. Thiazolopyrimidine modulators of trpv1
ATE485276T1 (de) 2006-08-08 2010-11-15 Millennium Pharm Inc Heteroarylverbindungen als hemmer der e1- aktivierenden enzyme
WO2008057402A2 (en) * 2006-11-02 2008-05-15 Cytovia, Inc. N-aryl-isoxazolopyrimidin-4-amines and related compounds as activators of caspases and inducers of apoptosis and the use thereof
AU2006350748A1 (en) 2006-11-16 2008-05-22 Pharmacopeia, Llc 7-substituted purine derivatives for immunosuppression
WO2008059368A2 (en) 2006-11-17 2008-05-22 Pfizer Products Inc. Fused 2-amino pyrimidine compounds and their use for the treatment of cancer
ES2571028T3 (es) * 2006-12-07 2016-05-23 Genentech Inc Compuestos inhibidores de fosfoinositida 3-cinasa y métodos de uso
CA2674875A1 (en) 2007-01-23 2008-07-31 Palau Pharma, S.A. Purine derivatives
MX2009007944A (es) 2007-01-26 2009-08-07 Irm Llc Compuestos y composiciones de purina como inhibidores de quinasa para el tratamiento de enfermedades relacionadas con plasmodium.
WO2008135232A1 (en) 2007-05-02 2008-11-13 Riccardo Cortese Use and compositions of purine derivatives for the treatment of proliferative disorders
CN101679456B (zh) * 2007-06-12 2012-09-05 霍夫曼-拉罗奇有限公司 噻唑并嘧啶类和它们作为磷脂酰肌醇3-激酶的抑制剂的应用
TWI434849B (zh) 2007-06-29 2014-04-21 Gilead Sciences Inc 類鐸(Toll-like)受體7之調節劑
WO2009013545A2 (en) * 2007-07-26 2009-01-29 Astrazeneca Ab Chemical compounds
WO2009027732A1 (en) * 2007-08-24 2009-03-05 Astrazeneca Ab 5-6-bicyclic heteroaromatic compounds with antibacterial activity
CA2704711C (en) * 2007-09-24 2016-07-05 Genentech, Inc. Thiazolopyrimidine p13k inhibitor compounds and methods of use
UA104010C2 (en) * 2008-12-18 2013-12-25 Эли Лилли Энд Компани Purine compounds
ES2543216T3 (es) * 2009-03-13 2015-08-17 Katholieke Universiteit Leuven, K.U. Leuven R&D Moduladores de tiazolopirimidina como agentes inmunosupresores
AR080711A1 (es) * 2010-03-31 2012-05-02 Lilly Co Eli Compuesto de piperazin-purina composicion farmaceutica que lo comprende y su uso para preparar un medicamento util para el tratamiento o prevencion del dolor

Also Published As

Publication number Publication date
WO2010103130A2 (en) 2010-09-16
EP2923734A1 (en) 2015-09-30
US9221822B2 (en) 2015-12-29
ES2543216T3 (es) 2015-08-17
ES2665277T3 (es) 2018-04-25
US8901132B2 (en) 2014-12-02
WO2010103130A3 (en) 2010-12-23
JP2015028088A (ja) 2015-02-12
JP6021880B2 (ja) 2016-11-09
CA2754890A1 (en) 2010-09-16
CA2754890C (en) 2018-01-16
CA2987743A1 (en) 2010-09-16
EP2923734B1 (en) 2018-01-10
US20150038494A1 (en) 2015-02-05
EP2405973A2 (en) 2012-01-18
US20120046278A1 (en) 2012-02-23
JP2012520269A (ja) 2012-09-06
EP2405973B1 (en) 2015-04-22

Similar Documents

Publication Publication Date Title
JP6021880B2 (ja) 免疫抑制剤としてのチアゾロピリミジン調節因子
US9573966B2 (en) Anti-cancer activity of novel bicyclic heterocycles
US9730944B2 (en) Antiviral activity of novel bicyclic heterocycles
US8232278B2 (en) Pyrido(3,2-D)pyrimidines and pharmaceutical compositions useful for treating hepatitis C
US20090036430A1 (en) Pyrido(3,2-d)pyrimidines and pharmaceutical compositions useful for medical treatment
US20080004285A1 (en) Pyrido(3,2-d)pyrimidines and pharmaceutical compositions useful for medical treatment
JP2011529918A (ja) Jak3阻害剤としてのピペリジン誘導体
JP2022526854A (ja) ホスファチジルイノシトール3-キナーゼ阻害剤
JP2008526704A (ja) ピリド(3,2−d)ピリミジンおよび医療処置に有用な医薬組成物
JPWO2002019975A1 (ja) 育毛剤

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130312

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20130312

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140617

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140916

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20141009

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20141110

R150 Certificate of patent or registration of utility model

Ref document number: 5647998

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees